Clinical trial
A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Acetate, Once Monthly Compared to Placebo
NCT04121221 is registered in ClinicalTrials.gov with Mapi Pharma Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Acetate, Once Monthly Compared to Placebo
- Lead sponsor
- Mapi Pharma Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 19, 2019
- Completion date
- June 13, 2023
- Enrollment
- 1,016 (actual)
- Sites
- 112
Conditions
As the registry lists them; a condition with its own page is linked.